Clinical studies have demonstrated that bsAbs targeting STEAP1 can be effective treatments for advanced PCa, with xaluritamig producing significant radiographic and PSA responses, confirming STEAP1 as a viable cancer target [66]. The gene discussed is STEAP1; the disease is cancer.